Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 256 Cr.
- Current Price ₹ 212
- High / Low ₹ 262 / 190
- Stock P/E 18.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 62.0 %
- ROE 64.0 %
- Face Value ₹ 10.0
Pros
Cons
- Working capital days have increased from 37.7 days to 64.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 87 | 131 | 132 | |
| 80 | 120 | 112 | |
| Operating Profit | 7 | 11 | 20 |
| OPM % | 8% | 9% | 15% |
| 0 | 0 | 1 | |
| Interest | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 7 | 11 | 19 |
| Tax % | 26% | 28% | 28% |
| 5 | 8 | 14 | |
| EPS in Rs | 40.46 | 58.73 | 102.73 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 75% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 64% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 1 | 1 | 1 |
| Reserves | 5 | 13 | 27 |
| 2 | 11 | 12 | |
| 17 | 15 | 13 | |
| Total Liabilities | 26 | 40 | 54 |
| 1 | 6 | 5 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 25 | 35 | 49 | |
| Total Assets | 26 | 40 | 54 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -0 | 5 | 1 | |
| -1 | -5 | -0 | |
| 1 | 1 | -1 | |
| Net Cash Flow | -0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 81 | 62 | 88 |
| Inventory Days | 10 | 25 | 27 |
| Days Payable | 65 | 37 | 34 |
| Cash Conversion Cycle | 25 | 50 | 81 |
| Working Capital Days | 23 | 25 | 65 |
| ROCE % | 67% | 62% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 Aug - EZRM begins construction of advanced nutraceutical manufacturing facility at JNPA SEZ, Maharashtra.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
5 Aug - Revised disclosure of Rs.1.48 Cr investment in subsidiary Easy Raw Materials via rights issue, maintaining 99% stake.
-
Announcement under Regulation 30 (LODR)-Acquisition
4 Aug - Chemkart invests Rs.1.48 Cr via rights issue in loss-making subsidiary for working capital.
-
Disclosure Under Regulation 30(5) Of SEBI LODR Regulations 2015.
15 Jul - Authorization of KMPs for materiality determination and disclosures under SEBI LODR regulations.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.